Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
Rhea-AI Summary
Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech focused on IL-1β pathway therapies for immune-mediated inflammatory diseases, will join the Russell 2000 and Russell 3000 indexes.
Inclusion is effective after the close of U.S. equity markets on June 26, 2026, increasing exposure to index-based and benchmark-driven investors.
Positive
- Inclusion in Russell 2000 index effective June 26, 2026
- Inclusion in broad-market Russell 3000 index
- Increased visibility among index funds and institutional managers using Russell benchmarks
Negative
- None.
News Market Reaction – AVTX
In the Jun 26 session, AVTX gained 1.11%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 23 | Board appointment | Positive | +4.4% | Added an experienced biopharma executive to the board after recent pipeline progress. |
| Jun 16 | Pipeline expansion | Positive | -1.9% | Advanced AVTX-010, a next‑generation anti‑IL‑1β antibody, expanding the HS pipeline. |
| May 22 | Inducement option grant | Neutral | -2.0% | Granted 34,000 stock options to a new employee under Nasdaq inducement rules. |
| May 13 | Earnings and updates | Positive | -0.5% | Reported positive Phase 2 LOTUS data and stronger cash from a large equity raise. |
| May 05 | Equity offering | Negative | +34.1% | Priced a sizeable public equity and pre‑funded warrant offering for Phase 3 funding. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AVTX often shows price moves that diverge from the apparent positivity of its news flow.
Key Terms
russell 2000® index financial
russell 3000® index financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that it will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 26, 2026.
The Russell 3000® Index measures the performance of the largest 3,000 publicly traded U.S. companies, representing approximately
For more information on the Russell 3000® Index and Russell 2000® Index and the Russell indexes reconstitution, visit the “Russell Reconstitution” section on the FTSE Russell website.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). In addition to HS, we’re exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. We are also advancing AVTX-010, a long-acting next-generation anti-IL-1β mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. For more information about Avalo, please visit www.avalotx.com.
Forward-Looking Statements
This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo’s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
or
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
